Lab device aims to predict which ovarian cancers resist chemo
NCT ID NCT07461207
Summary
This study aims to test a special lab device called the U-Cup bioreactor to see if it can predict whether a patient's ovarian cancer will respond to standard chemotherapy. Researchers will enroll 120 women newly diagnosed with high-grade serous ovarian cancer who have not yet had chemotherapy. The goal is to create a personalized testing platform that could help guide treatment decisions for patients whose cancers are resistant to standard drugs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE SEROUS OVARIAN CARCINOMA (HGSOC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Bologna, Bologna, 40138, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.